Short Interest in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Declines By 38.8%

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) saw a large decline in short interest during the month of December. As of December 31st, there was short interest totalling 93,300 shares, a decline of 38.8% from the December 15th total of 152,400 shares. Based on an average trading volume of 111,600 shares, the short-interest ratio is currently 0.8 days. Approximately 2.1% of the company’s shares are short sold.

Institutional Trading of Brainstorm Cell Therapeutics

A hedge fund recently bought a new stake in Brainstorm Cell Therapeutics stock. Armistice Capital LLC acquired a new position in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 7,917,653 shares of the biotechnology company’s stock, valued at approximately $2,680,000. Armistice Capital LLC owned 11.30% of Brainstorm Cell Therapeutics as of its most recent filing with the Securities and Exchange Commission. 14.33% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, StockNews.com lowered Brainstorm Cell Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, January 8th.

Brainstorm Cell Therapeutics Stock Performance

NASDAQ:BCLI traded up $0.01 during midday trading on Wednesday, reaching $2.05. 32,943 shares of the stock traded hands, compared to its average volume of 55,812. The stock has a market capitalization of $11.69 million, a P/E ratio of -0.43 and a beta of 0.29. Brainstorm Cell Therapeutics has a 12 month low of $1.05 and a 12 month high of $11.89. The company has a fifty day moving average of $1.76 and a 200 day moving average of $3.21.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.